Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Insamo launches to develop cyclic peptides

by Rowan Walrath
February 26, 2024 | A version of this story appeared in Volume 102, Issue 6

 

The University of California, Berkeley, has spun out Insamo, a start-up focused on making oral cyclic peptides, which would replace medicines that have so far only been available as injections or infusions. Insamo is using software tools to engineer oral macrocycles that can bind to their targets as well as antibodies can. Insamo has so far raised $12 million from investors including Merck & Co.’s MRL Ventures Fund.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.